In
Vitro Measurement and In Vivo Prediction of Combination Safety of
Rivaroxaban with Tyrosine Kinase Inhibitors: A Medication Safety
Assessment Study
Tingting Zhaoa,b #, Xuening Lia, b,
#,
Yanwei
Chenc, #, Dalong Wanga,
Liyan
Wangc,
Shan
Zhaod,
Changyuan
Wanga, b,
Qiang
Menga, b,
Huijun
Suna, b,
Kexin
Liua, b, Jingjing Wua, b*
aDepartment of Clinical Pharmacology, College of
Pharmacy, Dalian Medical University,
Dalian 116044, China.
bProvincial Key Laboratory for Pharmacokinetics and
Transport, Liaoning Dalian Medical University, Dalian, Liaoning, China.
cDepartment of Pharmacy, the First Affiliated Hospital
of Dalian Medical University, Dalian 116011, China.
dDalian
Institute of Chemical Physics, Chinese Academy of Sciences, Dalian
116023, China.
# These authors contributed equally to this work.
* Correspondence:
Dr. Jingjing Wu
ORCID: 0000-0002-5046-9996
Department of Clinical Pharmacology, College of pharmacy
Dalian Medical University
9 West
Section,
Lvshun South Road, Lvshunkou District, Dalian 116044, China